Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17183769 | 0.83 | TSHR (0.39) | TDP1CA1CA2GRIK1GRIK2 | |
| SCHEMBL13561365 | 0.81 | TSHR (0.30) | — | |
| SCHEMBL176067 | 0.80 | BHMT (0.38) | TDP1GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL9468089 | 0.80 | TDP1 (0.42) | TDP1GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL22952 | 0.79 | TET2 (0.48) | CA1CA2CA7CA14GRIK1 | |
| SCHEMBL21115790 | 0.79 | ALDH1A1 (0.35) | TDP1CA1CA2CA7CA14 | |
| SCHEMBL17183682 | 0.79 | TDP1 (0.38) | TDP1CA1CA2GRIK1GRIK2 | |
| SCHEMBL732388 | 0.78 | TDP1 (0.33) | TDP1 | |
| SCHEMBL17183761 | 0.78 | TDP1 (0.33) | TDP1CA1CA2 | |
| SCHEMBL913310 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4518865-A1 | METHODS OF TREATING NEUROINFLAMMATORY CONDITIONS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518866-A1 | METHODS OF TREATING FIBROSIS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518864-A1 | METHODS OF TREATING NEUROPATHIES | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4448100-A1 | USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | Athira Pharma, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-117986441-A | Oil displacement agent for improving recovery ratio of low-permeability sensitive heavy oil reservoir and preparation method thereof | 中国石油化工股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023215377-A1 | METHODS OF TREATING NEUROINFLAMMATORY CONDITIONS | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215376-A1 | METHODS OF TREATING NEUROPATHIES | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215378-A1 | METHODS OF TREATING FIBROSIS | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-4236944-A1 | BICYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF DISEASES | Athira Pharma, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023114456-A1 | USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | ATHIRA PHARMA, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022094400-A1 | BICYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF DISEASES | ATHIRA PHARMA, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20200223125-A1 | RESIN FOR NANOIMPRINTING, LAMINATE CONTAINING RESIN FOR NANOIMPRINTING, PRINTED BOARD CONTAINING RESIN FOR NANOIMPRINTING, AND METHOD FOR PRODUCING NANOIMPRINT SUBSTRATE | JAPAN SCIENCE & TECH AGENCY (JP) | 2020-07-16 | — | — | US | disclosed |
| US-20150298387-A1 | RESIN FOR NANOIMPRINTING, LAMINATE CONTAINING RESIN FOR NANOIMPRINTING, PRINTED BOARD CONTAINING RESIN FOR NANOIMPRINTING, AND METHOD FOR PRODUCING NANOIMPRINT SUBSTRATE | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2015-10-22 | — | — | US | disclosed |
| US-8303943-B2 | Ampholytic copolymer based on quaternized nitrogen-containing monomers | BASF SE (DE) | 2012-11-06 | — | — | US | disclosed |
| CN-101516934-B | Amphoteric copolymers based on quaternized nitrogen-containing monomers | BASF SE | 2012-07-18 | — | — | CN | disclosed |
| US-20100068156-A1 | AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS | BASF SE (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-2064253-B1 | AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS | BASF SE (DE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009103735-A1 | COMPOSITION CONTAINING AN AMPHOLYTIC COPOLYMER ON THE BASIS OF QUATERNISED MONOMERS CONTAINING NITROGEN AND AT LEAST ONE POLYMER THAT DIFFERS FROM SAID COPOLYMER, AND USE THEREOF | BASF SE (DE) | 2009-08-27 | — | — | WO | disclosed |
| EP-2064253-A1 | AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS | BASF SE (DE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008031892-A1 | AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS | BASF SE (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068156-A1 | AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS | NGLY1, NAAA, NIT2 | TDP1 1288/4885CA1 468/4885CA2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.